ClearGuard HD barrier cap,
does it really help with Reduced positive blood-culture rate versus Tego connector plus Curos disinfecting cap?
research showsThe grade is C. In the primary analysis of a 40-facility cluster-randomized trial, positive blood cultures among 1,671 patients were 23 over 83,064 catheter-days, 0.28 per 1,000 days, with ClearGuard versus 75 over 100,042 days, 0.75 per 1,000 days, with Tego plus Curos; IRR 0.37 (95% CI 0.20 to 0.68; P=.001). The large difference is real, but the endpoint is a laboratory result rather than clinical bloodstream infection itself, and all supporting trials were manufacturer sponsored, giving C with 50 points.
ads claimClearGuard truly reduced positive blood cultures versus Tego plus Curos. This cannot be rewritten as established reductions in sepsis, hospitalization, or death, and independent replication outside the manufacturer program is needed.
Useful facts when choosing a product
- ClearGuard has chlorhexidine coating on a rod entering the catheter hub and on its threads, and it was replaced at every dialysis session.
- The control used a weekly Tego connector and a 70% isopropyl-alcohol Curos cap replaced each dialysis session.
- The primary endpoint was positive blood-culture rate; confirmed catheter-related infection and hospitalization were exploratory.
Chamgap Semantic Classification Code
Candidate index · review held
UNK.clearguard-hd-chlorhexidine-coated-intraluminal-barrier-cap-replaced-at-every-hemodialysis-session.intravenous.positive-blood-culture-rate.reduce.activeUnknown > ClearGuard HD chlorhexidine-coated intraluminal barrier cap replaced at every hemodialysis session > Intravenous > positive blood-culture rate > Reduction claim > Active comparator
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
Brunelli SM, Van Wyck DB, Njord L, Ziebol RJ, Lynch LE, and Killion DP pair-matched 40 facilities on baseline bloodstream-infection rate, CVC population, and geography, then assigned 20 per arm with a computer algorithm. Of 1,911 enrolled, nine were excluded for heparin allergy; 231 of 1,902 treated for 21 days or less were removed, leaving 1,671 in the primary analysis. Brunelli was affiliated with DaVita Clinical Research, Van Wyck and Njord with DaVita, and Ziebol, Lynch, and Killion with Pursuit Vascular.
Why this is classified as C (50)
A large laboratory-endpoint difference was found, but it was not direct clinical infection evidence, and only manufacturer-sponsored evidence was identified. Exclusion of short users and active-control-only design give C with 50 points.
Counterpoint. The stricter infection analysis pointed in the same direction. Independent funding with clinical infection or hospitalization as a prespecified primary endpoint could change the grade.
Rejudgment record. Cross-check applied — The article, NCT record, and affiliations were cross-checked for the laboratory primary endpoint, facility randomization, 21-day exclusion population, IRR and confidence interval, manufacturer funding, and employee authorship.
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E+ | Meets the clinically important threshold |
Stored derived and displayed grades match; this is not a current recalculation or validity check (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduced positive blood-culture rate | C | The rate was lower, IRR 0.37, but evidence used a laboratory endpoint and was manufacturer-only. |
| Reduced infection-related hospitalization | D | The exploratory analysis was not significant, IRR 0.55, P=.5. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Brunelli SM, Van Wyck DB, Njord L, Ziebol RJ, Lynch LE, Killion DP, 2018 | Open cluster-randomized active-control trial at 40 facilities | 1,911 enrolled, 1,902 treated, and 1,671 in the primary analysis, 826 and 845 | Sponsored by Pursuit Vascular, which paid DaVita Clinical Research; three manufacturer-employed authors | Positive blood cultures per 1,000 CVC-days | 0.28 (23/83,064 CVC-days) versus 0.75 (75/100,042 CVC-days); IRR 0.37 (95% CI 0.20 to 0.68), P=.001 | Manufacturer-only laboratory-endpoint evidence |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-08-14).
Final verification and publication gate: Codex · Evidence date: 2026-08-14 · Corrections: none
Cite this verdict
[Chamgap] ClearGuard HD barrier cap x positive blood cultures — Evidence Grade C·50. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/clearguard-hd-caps-positive-blood-cultures/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.